Pick any two of the 81 evidence-graded compounds and weigh them against each other — six derived evidence dimensions, hallmark overlap, studied dose, and published bioavailability. Where the data can't support a call, it says so instead of guessing.
Comparing any two of 81 evidence-graded compounds. This comparison has its own shareable link.
Pterostilbene carries the stronger overall evidence profile across 6 of 6 comparable dimensions.
Documented synergy
The library documents Trans-Resveratrol and Pterostilbene as a synergistic pairing — they are recorded as complementary, not alternatives.
Each bar grows outward from the centre line — Trans-Resveratrol to the left, Pterostilbene to the right. Higher is stronger. Values are normalised 0–100 ratings, not percentages — the bioavailability rating is the scoring model's absorption grade, which is a different measure from the published oral-bioavailability percentage in the table below. A dimension neither side can support is left uncalled rather than scored as zero.
Human evidence: Trans-Resveratrol leads by 4 points.
Trans-Resveratrol leads by 4
Clinical evidence: Too close to call.
Too close to call
Mechanistic strength: Pterostilbene leads by 32 points.
Pterostilbene leads by 32
Safety: Too close to call.
Too close to call
Bioavailability: Pterostilbene leads by 62 points.
Pterostilbene leads by 62
Longevity relevance: Pterostilbene leads by 7 points.
Pterostilbene leads by 7
Where these two overlap on the hallmarks of aging — and where each one reaches something the other doesn't.
Only Trans-Resveratrol
Only Pterostilbene
| Measure | Trans-Resveratrol | Pterostilbene | Verdict |
|---|---|---|---|
| Evidence tier | Tier B | Tier B | Graded independently |
| TNiC Score | 62 | 73 | Pterostilbene leads |
| Human evidence (rating 0–100) | 70 | 66 | Trans-Resveratrol leads |
| Clinical evidence (rating 0–100) | 68 | 68 | Too close to call |
| Mechanistic strength (rating 0–100) | 42 | 74 | Pterostilbene leads |
| Safety (rating 0–100) | 82 | 79 | Too close to call |
| Bioavailability (rating 0–100) | 30 | 92 | Pterostilbene leads |
| Longevity relevance (rating 0–100) | 68 | 75 | Pterostilbene leads |
| Studied dose | 150–500mg trans-resveratrol | 50–150mg pterostilbene | Not comparable — different targets |
| Timing | PM | PM | — |
| Published oral bioavailability (measured %) | 72% | 82% | — |
| Indexed studies | 3 | 1 | Cited on each deep-dive |